Leading multinational pharmaceutical companies operating
in India have outlined various strategies to tap the Rs
18,000-crore domestic market in the post-2005 patent regime.
such as Glaxo, Pfizer, Novartis, Eli Lilly and Aventis
Pharma are in the process of finalising their Indian strategy
by rationalising their product portfolio with a focus
on more patented products, contract research and contract
manufacturing with domestic pharma corporates, and aggressive
marketing and sales by forming revamped marketing teams.
global pharma industry is valued at $300 billion and India''s
share is only 1.6 per cent. Says Glaxo SmithKline India
managing director S Kalyanasundaram: "We will focus
30 of our power brands in various therapeutic segment
and we expect them to grow by over 50 per cent in the
Motilal Oswal Securities pharma analyst Shahina Mukadam:
"India is a signatory to the World Trade Organisation
and by 2005, the country will recognise product patents.
The Second Patent Amendment Act was passed by the Parliament,
though there are some difference of opinion on compulsory
licensing, in 2002. It aligns Indian law with those recommended
by trade-related property rights. That effectively means
that patent protection will be extended to all products
patented after 1995, if they are introduced here and multinational
corporations are focusing on this currently."
US-based pharma firm Pfizer has said that the company
has been focusing on 12 products from the existing portfolio.
Bangalore-based AstraZeneca trimmed its product portfolio
to 14 patented products from the earlier 35.
Pfizer India managing director Hocine Sidi Said: "We
will continuously rationalise products and introduce new
patented ones in the Indian market at the same time as
the rest of the world. Post-2005, we expect more research-driven
collaborations in India." Pfizer Inc has already
set up a four-member team to evaluate the business possibilities
in India in the post-patent regime.
move towards patent regime also attracts companies to
look at India as their centre for research and development
as well as for contract research. The US-based Eli Lilly
has started to source bulk drugs such as Nizatidine and
Methohexital for its global requirements from Shasun Chemicals.
company is also working for another seven molecules for
Lilly''s developing industrial production process, say
industry sources. Similarly, 35-40 per cent of the global
manufacturing volumes of GSK worldwide, in number of tablets,
liquid drugs and injectables, is sourced from India.